U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07798375) titled 'A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration' on Aug. 27.
Brief Summary: This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD)
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Neovascular Age Related Macular Degeneration(nAMD)
Intervention:
BIOLOGICAL: VIS-101 6.0mg High concentration
VIS-101 will be administered by in...